Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Adolescents With Active Moderate to Severe Hidradenitis Suppurativa
NCT06768671Phase 3Active, not recruiting
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 3 trial of sonelokimab in hidradenitis suppurativa (HS), sponsored by MoonLake Immunotherapeutics. Started Dec 2024; status: active, not recruiting.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06768671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768671.